Merck facts and figures. This document provides key information on the pharmaceutical player Merck. It covers financials, strategic aspects and other KPI's as well as information on corporate responsibility topics.
Merck compliance and ethics - the Merck code for responsible business conductMerck-Responsibility
Merck's code of conduct which describes the expectations on ethical and compliant business conduct from Merck's employees and company officers. A state-of-the art code of conduct from Merck that covers all areas of responsible business conduct.
At the 2nd BME Global Pharma Supply Chain Congress, taking place March 20 to 23 2017 in Frankfurt/Germany, around 450 Pharma & Medical Device Top Supply Chain Executives will gather with international Healthcare Institutions to discuss patient-centric supply chain models as key enabler to improve access to medicine for patients worldwide.
Merck & Co. is one of the largest pharmaceutical companies established in 1891. It manufactures and markets a broad range of healthcare products for human and animal use. Merck has annual revenue of $27.4 billion and employs over 61,500 people worldwide. Some of Merck's major products include vaccines, prescription drugs, consumer health products, and animal health medicines. One of Merck's prescription drugs is lisinopril, an ACE inhibitor used to treat hypertension, heart failure, and diabetic complications. It has annual global sales of over $1 billion.
Merck Brazil - Facts and Figures of Merck Pharmaceutical Company in BrazilMerck-Responsibility
The multinational pharma company Merck has been active in Brazil for many years. Merck facts and figures. This document provides key information on the global pharmaceutical player Merck. It covers financials, strategic aspects and other KPI's as well as information on corporate responsibility topics.
Merck corporate social responsibility - Merck CSR report 2012Merck-Responsibility
This is the Merck CSR report 2012. The multinational pharmaceutical company Merck provides for state-of-the-art corporate social responsibility standards and gives a comprehensive view on their CSR activities.
This document announces the 11th Annual Biosimilars UK conference taking place October 29-31, 2012 in London. It will bring together major pharmaceutical companies, regulatory bodies, CROs, CMOs, and law firms to discuss strategies for competing in the complex biosimilars market. Key topics will include the latest regulatory guidelines, financial viability, patent strategies, approval pathways, legal issues, preclinical/clinical challenges, the roles of the US and European markets, pricing/reimbursement, and pharmacovigilance. The goal is to help participants maximize opportunities in this changing landscape. Major sponsors include Merck Millipore and United BioSource Corporation.
The pre-conference workshop will provide an interactive forum for attendees to engage with leaders on regulatory challenges surrounding biosimilars in the US and EU. The workshop will compare the EU's experience in introducing biosimilars, lessons learned, and new developments, with the recent introduction of biosimilar legislation in the US. Attendees will have the opportunity to participate in group discussions and Q&A sessions on these topics led by experts Dr. Angela Thomas of the MHRA and Dr. Anita O'Connor. The small group setting is designed to foster maximum interaction between leaders and delegates.
Merck compliance and ethics - the Merck code for responsible business conductMerck-Responsibility
Merck's code of conduct which describes the expectations on ethical and compliant business conduct from Merck's employees and company officers. A state-of-the art code of conduct from Merck that covers all areas of responsible business conduct.
At the 2nd BME Global Pharma Supply Chain Congress, taking place March 20 to 23 2017 in Frankfurt/Germany, around 450 Pharma & Medical Device Top Supply Chain Executives will gather with international Healthcare Institutions to discuss patient-centric supply chain models as key enabler to improve access to medicine for patients worldwide.
Merck & Co. is one of the largest pharmaceutical companies established in 1891. It manufactures and markets a broad range of healthcare products for human and animal use. Merck has annual revenue of $27.4 billion and employs over 61,500 people worldwide. Some of Merck's major products include vaccines, prescription drugs, consumer health products, and animal health medicines. One of Merck's prescription drugs is lisinopril, an ACE inhibitor used to treat hypertension, heart failure, and diabetic complications. It has annual global sales of over $1 billion.
Merck Brazil - Facts and Figures of Merck Pharmaceutical Company in BrazilMerck-Responsibility
The multinational pharma company Merck has been active in Brazil for many years. Merck facts and figures. This document provides key information on the global pharmaceutical player Merck. It covers financials, strategic aspects and other KPI's as well as information on corporate responsibility topics.
Merck corporate social responsibility - Merck CSR report 2012Merck-Responsibility
This is the Merck CSR report 2012. The multinational pharmaceutical company Merck provides for state-of-the-art corporate social responsibility standards and gives a comprehensive view on their CSR activities.
This document announces the 11th Annual Biosimilars UK conference taking place October 29-31, 2012 in London. It will bring together major pharmaceutical companies, regulatory bodies, CROs, CMOs, and law firms to discuss strategies for competing in the complex biosimilars market. Key topics will include the latest regulatory guidelines, financial viability, patent strategies, approval pathways, legal issues, preclinical/clinical challenges, the roles of the US and European markets, pricing/reimbursement, and pharmacovigilance. The goal is to help participants maximize opportunities in this changing landscape. Major sponsors include Merck Millipore and United BioSource Corporation.
The pre-conference workshop will provide an interactive forum for attendees to engage with leaders on regulatory challenges surrounding biosimilars in the US and EU. The workshop will compare the EU's experience in introducing biosimilars, lessons learned, and new developments, with the recent introduction of biosimilar legislation in the US. Attendees will have the opportunity to participate in group discussions and Q&A sessions on these topics led by experts Dr. Angela Thomas of the MHRA and Dr. Anita O'Connor. The small group setting is designed to foster maximum interaction between leaders and delegates.
Biopharmaceuticals are an essential therapeutic option accounting for a substantial part of the global therapeutic market. With the patents of many blockbuster drugs coming to an end, an opportunity has arisen for the manufacture and approval of biosimilars. Visiongain\'s 9th Biosimilars Conference will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscape and challenges in clinical development, to the legal and economic aspects.
This document provides information about Merck Pharmaceuticals. It begins with introductions of the instructor, group members, and team for the project. It then discusses the differences between a team and group. Next, it provides background on Merck Pharmaceuticals, including its history, founders, headquarters, values, and presence in Pakistan. It includes a mind map outlining the introduction, positioning, product positioning, improving the product line, differentiation, and conclusion. It discusses Merck's positioning strategy, priority areas of performance, people, and technology. It also outlines how product positioning can improve marketing. Finally, it provides details on Merck's product line and how it differentiates itself from competitors like Pfizer, Roche, and
This document provides an overview of Venus Glucose Pvt. Ltd., an Indian pharmaceutical company. It discusses the company's history since 1989, key milestones and expansions. The company has manufacturing facilities in India and Germany, and focuses on research and development, generics, and key therapeutic areas like analgesics, antibiotics and anti-diabetics. The document also outlines the company's vision, mission and focus on developing drugs for antimicrobial resistance. It introduces the executive team and provides an organizational structure.
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
This document provides information about the 10th Annual Conference on RNA Therapeutics taking place on February 20-21, 2019 in London. It outlines the chairs, guest speakers, and key speakers at the conference, as well as featured highlights and topics to be discussed. Some of the topics to be covered include the clinical progress of spherical nucleic acids with Exicure, Sanofi's strategies for oligonucleotide delivery, ProQR's plans for oligonucleotide supply, and the development of self-amplifying mRNA vaccines at GSK. The document provides an agenda and schedule for the two-day conference.
The document discusses the development of mRNA therapeutics and the manufacturing challenges associated with them. Some key points:
- mRNA vaccines have advantages over traditional vaccines like speed of development and flexibility, but manufacturing challenges remain.
- Challenges include the supply of plasmid DNA, in vitro transcription processes, purification difficulties due to mRNA size/properties, and lipid nanoparticle formulation/delivery.
- Overcoming these challenges will help realize the potential of mRNA technology for a wide range of applications from mass vaccines to personalized cancer immunotherapies, which may require flexible small-batch manufacturing capabilities. Addressing production bottlenecks and developing standardized tools/processes can accelerate development.
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies. The Company is developing a pharmaceutical pipeline to improve drug delivery technologies and capabilities for patients, physicians, and payers through transdermal delivery technologies. Nutriband’s lead product is its AVERSA® technology. AVERSA® abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential, such as opioids. The Company’s first application for AVERSA® is an abuse deterrent fentanyl transdermal patch which it is developing to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid based pain treatments safe for all who need them. AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with patent prosecution in the US and Canada. Nutriband has made sure to target all large applicable markets and its global patent protection has opened up many opportunities for the Company to make a big impact on the safety profile of drugs globally.
10 Most Efficient Drug Delivery Solution Providers in 2023V2_compressed.pdfinsightscare
Insights Care’s latest edition, 10 Most Efficient Drug Delivery Solution Providers in 2023, navigates you to the rapidly changing healthcare landscape.
Microneedles for drug delivery patent landscape 2020 flyerKnowmade
Report’s Key Features
• PDF with > 140 slides
• Excel file > 2,450 patent families
• IP trends, including time-evolution of published patents, and countries of patent filings
• Patents’ legal status
• Ranking of main patent assignees
• Key players’ IP position and relative strength of their patent portfolios
• Summary of the IP related to applications: Cancer therapy, Cosmetic, Diabetes, Ophthalmic, Pain management and Vaccine.
• Summary of the IP related to technologies: Applicators, housing, Coated, Hollow, Porous, Soluble, Hydrogel and Solid microneedles.
• Analysis of patent oppositions (Europe) and review of key patents.
• Excel database containing all patents analyzed in the report, including applications and technologies segmentations
Cooper Pharma corporate presentation by Ayman CHEIKH LAHLOU, CEO, for mHealth...Levi Shapiro
Ayman CHEIKH LAHLOU, CEO, Cooper Pharma, presents Apirl 21, 2021, to the mHealth Israel community. Cooper at a Glance: History, DNA & Key Figures. Commitments Towards Quality. Partnerships in Licensing. Cooper Pharma’s vision is to be a leading player in the Healthcare and Pharmaceutical sector
at local and regional levels, through a large range of products and services. Make medicines more available to patients by:
Producing and marketing branded generic and innovate drugs of the highest quality at the best price. Making all drugs available at any time and everywhere in Morocco. Manufacturing of over 200 specialties in nearly 300 presentations both for its own range of branded generics and on behalf of international pharmaceutical companies. Cooper Pharma focuses part of its strategy on the international market,
thus considering exports as a vector of development and
competitiveness. Through its wholesale activity with 9 distribution companies across
Morocco, Cooper Pharma can provide its citizens with all imported & manufactured drugs with a reduced lead times to pharmacies. Therapeutic areas include GASTROENTEROLOGY, GENERAL MEDICINE &
ANTIBIOTHERAPY, WOMEN’S HEALTH, SELF MEDICATION, CLINICS, HOSPITALS & ONCOLOGY, SPECIALTY. THERE IS STILL ROOM FOR IMPROVEMENT TO UPGRADE
PATIENT & PHYSICIAN EXPERIENCES IN MOROCCO
Further progress could be made. We need to make it happen in short & middle term with long-term realistic targets by leveraging experience from others.
Status of the Microfluidics Industry 2019 report by Yole Développement Yole Developpement
Diversification of microfluidic technologies has led to burgeoning new applications and market growth, driving players’ interest and M&A.
More information on https://www.i-micronews.com/products/status-of-the-microfluidics-industry-2019/
Merck has undergone several strategic changes over the last 10 years driven by external factors. Competitive pressures from other major pharmaceutical companies like Pfizer and GlaxoSmithKline prompted Merck to pursue acquisitions and diversify into new business areas. Regulations from government agencies also impacted Merck's marketing strategies and product liability costs. Economic conditions negatively affected revenue, requiring cost cutting measures and layoffs. Merck adapted by shifting research focus, pursuing partnerships and licenses, and targeting emerging international markets through acquisitions and new facilities.
Lyndon Foster is a life science executive with over 30 years of experience in research, business development, and leadership. He has held roles such as Chief Operating Officer and President/Owner of his own company. He has extensive expertise in areas such as molecular biology, neuroscience, and stem cell research. Throughout his career, he has successfully led technical operations and services teams, helping companies achieve substantial growth.
The costumer experience is nowadays more important than ever for brands that want to succeed in creating a good customer-centric strategy. Consumers are demanding personalized offers and products. Brands have the opportunity to exploit digitization in order to create added value whilst capturing relevant data from their clients.
Our digital solution integrate the product features and consumer’s personal context and characteristics. The aim is to accompany consumers in a personalized manner, making the customer journey easier, and adding value.
Would you like to know how? Check out this presentation.
Industrial enzymes Market PPT: Trends and Dynamics, Drivers, Competitive land...IMARC Group
According to the latest report by IMARC Group,the global industrial enzymes market grew at a CAGR of 6% during 2015-2020.
Industrial enzymes are catalysts that are widely used to boost and accelerate chemical reactions across various industrial processes.
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...IMARC Group
The document summarizes a report by IMARC Group on the global oncology biosimilars market. It discusses the growth of the market driven by the rising prevalence of cancer and upcoming patent expiries. Oncology biosimilars are similar to original biologics but are more affordable, improving access to treatment. The report analyzes the market by drug type, distribution channel, and region. It also profiles the major players in the industry.
Krishgen is an Indian biotech company established in 2003 that focuses on developing tools for the life sciences and agri industries. It has experienced strong growth, with revenues reaching $5 million in 2011. The company provides products and services related to medical diagnostics, drug discovery research, biopharmaceuticals, and plant/food sciences.
Krishgen is an Indian biotech company established in 2003 that focuses on developing tools for the life sciences and agriculture industries. It has experienced strong growth, with revenues reaching $5 million in 2011. Krishgen provides products and services related to medical diagnostics, drug discovery research, biopharmaceuticals, and plant/food sciences. It aims to enable breakthroughs in biological research and disease treatment.
Part 2 Deep Dive: Navigating the 2024 Slowdownjeffkluth1
Introduction
The global retail industry has weathered numerous storms, with the financial crisis of 2008 serving as a poignant reminder of the sector's resilience and adaptability. However, as we navigate the complex landscape of 2024, retailers face a unique set of challenges that demand innovative strategies and a fundamental shift in mindset. This white paper contrasts the impact of the 2008 recession on the retail sector with the current headwinds retailers are grappling with, while offering a comprehensive roadmap for success in this new paradigm.
Biopharmaceuticals are an essential therapeutic option accounting for a substantial part of the global therapeutic market. With the patents of many blockbuster drugs coming to an end, an opportunity has arisen for the manufacture and approval of biosimilars. Visiongain\'s 9th Biosimilars Conference will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscape and challenges in clinical development, to the legal and economic aspects.
This document provides information about Merck Pharmaceuticals. It begins with introductions of the instructor, group members, and team for the project. It then discusses the differences between a team and group. Next, it provides background on Merck Pharmaceuticals, including its history, founders, headquarters, values, and presence in Pakistan. It includes a mind map outlining the introduction, positioning, product positioning, improving the product line, differentiation, and conclusion. It discusses Merck's positioning strategy, priority areas of performance, people, and technology. It also outlines how product positioning can improve marketing. Finally, it provides details on Merck's product line and how it differentiates itself from competitors like Pfizer, Roche, and
This document provides an overview of Venus Glucose Pvt. Ltd., an Indian pharmaceutical company. It discusses the company's history since 1989, key milestones and expansions. The company has manufacturing facilities in India and Germany, and focuses on research and development, generics, and key therapeutic areas like analgesics, antibiotics and anti-diabetics. The document also outlines the company's vision, mission and focus on developing drugs for antimicrobial resistance. It introduces the executive team and provides an organizational structure.
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
This document provides information about the 10th Annual Conference on RNA Therapeutics taking place on February 20-21, 2019 in London. It outlines the chairs, guest speakers, and key speakers at the conference, as well as featured highlights and topics to be discussed. Some of the topics to be covered include the clinical progress of spherical nucleic acids with Exicure, Sanofi's strategies for oligonucleotide delivery, ProQR's plans for oligonucleotide supply, and the development of self-amplifying mRNA vaccines at GSK. The document provides an agenda and schedule for the two-day conference.
The document discusses the development of mRNA therapeutics and the manufacturing challenges associated with them. Some key points:
- mRNA vaccines have advantages over traditional vaccines like speed of development and flexibility, but manufacturing challenges remain.
- Challenges include the supply of plasmid DNA, in vitro transcription processes, purification difficulties due to mRNA size/properties, and lipid nanoparticle formulation/delivery.
- Overcoming these challenges will help realize the potential of mRNA technology for a wide range of applications from mass vaccines to personalized cancer immunotherapies, which may require flexible small-batch manufacturing capabilities. Addressing production bottlenecks and developing standardized tools/processes can accelerate development.
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies. The Company is developing a pharmaceutical pipeline to improve drug delivery technologies and capabilities for patients, physicians, and payers through transdermal delivery technologies. Nutriband’s lead product is its AVERSA® technology. AVERSA® abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential, such as opioids. The Company’s first application for AVERSA® is an abuse deterrent fentanyl transdermal patch which it is developing to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid based pain treatments safe for all who need them. AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with patent prosecution in the US and Canada. Nutriband has made sure to target all large applicable markets and its global patent protection has opened up many opportunities for the Company to make a big impact on the safety profile of drugs globally.
10 Most Efficient Drug Delivery Solution Providers in 2023V2_compressed.pdfinsightscare
Insights Care’s latest edition, 10 Most Efficient Drug Delivery Solution Providers in 2023, navigates you to the rapidly changing healthcare landscape.
Microneedles for drug delivery patent landscape 2020 flyerKnowmade
Report’s Key Features
• PDF with > 140 slides
• Excel file > 2,450 patent families
• IP trends, including time-evolution of published patents, and countries of patent filings
• Patents’ legal status
• Ranking of main patent assignees
• Key players’ IP position and relative strength of their patent portfolios
• Summary of the IP related to applications: Cancer therapy, Cosmetic, Diabetes, Ophthalmic, Pain management and Vaccine.
• Summary of the IP related to technologies: Applicators, housing, Coated, Hollow, Porous, Soluble, Hydrogel and Solid microneedles.
• Analysis of patent oppositions (Europe) and review of key patents.
• Excel database containing all patents analyzed in the report, including applications and technologies segmentations
Cooper Pharma corporate presentation by Ayman CHEIKH LAHLOU, CEO, for mHealth...Levi Shapiro
Ayman CHEIKH LAHLOU, CEO, Cooper Pharma, presents Apirl 21, 2021, to the mHealth Israel community. Cooper at a Glance: History, DNA & Key Figures. Commitments Towards Quality. Partnerships in Licensing. Cooper Pharma’s vision is to be a leading player in the Healthcare and Pharmaceutical sector
at local and regional levels, through a large range of products and services. Make medicines more available to patients by:
Producing and marketing branded generic and innovate drugs of the highest quality at the best price. Making all drugs available at any time and everywhere in Morocco. Manufacturing of over 200 specialties in nearly 300 presentations both for its own range of branded generics and on behalf of international pharmaceutical companies. Cooper Pharma focuses part of its strategy on the international market,
thus considering exports as a vector of development and
competitiveness. Through its wholesale activity with 9 distribution companies across
Morocco, Cooper Pharma can provide its citizens with all imported & manufactured drugs with a reduced lead times to pharmacies. Therapeutic areas include GASTROENTEROLOGY, GENERAL MEDICINE &
ANTIBIOTHERAPY, WOMEN’S HEALTH, SELF MEDICATION, CLINICS, HOSPITALS & ONCOLOGY, SPECIALTY. THERE IS STILL ROOM FOR IMPROVEMENT TO UPGRADE
PATIENT & PHYSICIAN EXPERIENCES IN MOROCCO
Further progress could be made. We need to make it happen in short & middle term with long-term realistic targets by leveraging experience from others.
Status of the Microfluidics Industry 2019 report by Yole Développement Yole Developpement
Diversification of microfluidic technologies has led to burgeoning new applications and market growth, driving players’ interest and M&A.
More information on https://www.i-micronews.com/products/status-of-the-microfluidics-industry-2019/
Merck has undergone several strategic changes over the last 10 years driven by external factors. Competitive pressures from other major pharmaceutical companies like Pfizer and GlaxoSmithKline prompted Merck to pursue acquisitions and diversify into new business areas. Regulations from government agencies also impacted Merck's marketing strategies and product liability costs. Economic conditions negatively affected revenue, requiring cost cutting measures and layoffs. Merck adapted by shifting research focus, pursuing partnerships and licenses, and targeting emerging international markets through acquisitions and new facilities.
Lyndon Foster is a life science executive with over 30 years of experience in research, business development, and leadership. He has held roles such as Chief Operating Officer and President/Owner of his own company. He has extensive expertise in areas such as molecular biology, neuroscience, and stem cell research. Throughout his career, he has successfully led technical operations and services teams, helping companies achieve substantial growth.
The costumer experience is nowadays more important than ever for brands that want to succeed in creating a good customer-centric strategy. Consumers are demanding personalized offers and products. Brands have the opportunity to exploit digitization in order to create added value whilst capturing relevant data from their clients.
Our digital solution integrate the product features and consumer’s personal context and characteristics. The aim is to accompany consumers in a personalized manner, making the customer journey easier, and adding value.
Would you like to know how? Check out this presentation.
Industrial enzymes Market PPT: Trends and Dynamics, Drivers, Competitive land...IMARC Group
According to the latest report by IMARC Group,the global industrial enzymes market grew at a CAGR of 6% during 2015-2020.
Industrial enzymes are catalysts that are widely used to boost and accelerate chemical reactions across various industrial processes.
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...IMARC Group
The document summarizes a report by IMARC Group on the global oncology biosimilars market. It discusses the growth of the market driven by the rising prevalence of cancer and upcoming patent expiries. Oncology biosimilars are similar to original biologics but are more affordable, improving access to treatment. The report analyzes the market by drug type, distribution channel, and region. It also profiles the major players in the industry.
Krishgen is an Indian biotech company established in 2003 that focuses on developing tools for the life sciences and agri industries. It has experienced strong growth, with revenues reaching $5 million in 2011. The company provides products and services related to medical diagnostics, drug discovery research, biopharmaceuticals, and plant/food sciences.
Krishgen is an Indian biotech company established in 2003 that focuses on developing tools for the life sciences and agriculture industries. It has experienced strong growth, with revenues reaching $5 million in 2011. Krishgen provides products and services related to medical diagnostics, drug discovery research, biopharmaceuticals, and plant/food sciences. It aims to enable breakthroughs in biological research and disease treatment.
Similar to Merck facts and figures - Merck company profile 2012 (20)
Part 2 Deep Dive: Navigating the 2024 Slowdownjeffkluth1
Introduction
The global retail industry has weathered numerous storms, with the financial crisis of 2008 serving as a poignant reminder of the sector's resilience and adaptability. However, as we navigate the complex landscape of 2024, retailers face a unique set of challenges that demand innovative strategies and a fundamental shift in mindset. This white paper contrasts the impact of the 2008 recession on the retail sector with the current headwinds retailers are grappling with, while offering a comprehensive roadmap for success in this new paradigm.
Discover timeless style with the 2022 Vintage Roman Numerals Men's Ring. Crafted from premium stainless steel, this 6mm wide ring embodies elegance and durability. Perfect as a gift, it seamlessly blends classic Roman numeral detailing with modern sophistication, making it an ideal accessory for any occasion.
https://rb.gy/usj1a2
4 Benefits of Partnering with an OnlyFans Agency for Content Creators.pdfonlyfansmanagedau
In the competitive world of content creation, standing out and maximising revenue on platforms like OnlyFans can be challenging. This is where partnering with an OnlyFans agency can make a significant difference. Here are five key benefits for content creators considering this option:
The Most Inspiring Entrepreneurs to Follow in 2024.pdfthesiliconleaders
In a world where the potential of youth innovation remains vastly untouched, there emerges a guiding light in the form of Norm Goldstein, the Founder and CEO of EduNetwork Partners. His dedication to this cause has earned him recognition as a Congressional Leadership Award recipient.
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Final ank Satta Matka Dpbos Final ank Satta Matta Matka 143 Kalyan Matka Guessing Final Matka Final ank Today Matka 420 Satta Batta Satta 143 Kalyan Chart Main Bazar Chart vip Matka Guessing Dpboss 143 Guessing Kalyan night
SATTA MATKA SATTA FAST RESULT KALYAN TOP MATKA RESULT KALYAN SATTA MATKA FAST RESULT MILAN RATAN RAJDHANI MAIN BAZAR MATKA FAST TIPS RESULT MATKA CHART JODI CHART PANEL CHART FREE FIX GAME SATTAMATKA ! MATKA MOBI SATTA 143 spboss.in TOP NO1 RESULT FULL RATE MATKA ONLINE GAME PLAY BY APP SPBOSS
Call8328958814 satta matka Kalyan result satta guessing➑➌➋➑➒➎➑➑➊➍
Satta Matka Kalyan Main Mumbai Fastest Results
Satta Matka ❋ Sattamatka ❋ New Mumbai Ratan Satta Matka ❋ Fast Matka ❋ Milan Market ❋ Kalyan Matka Results ❋ Satta Game ❋ Matka Game ❋ Satta Matka ❋ Kalyan Satta Matka ❋ Mumbai Main ❋ Online Matka Results ❋ Satta Matka Tips ❋ Milan Chart ❋ Satta Matka Boss❋ New Star Day ❋ Satta King ❋ Live Satta Matka Results ❋ Satta Matka Company ❋ Indian Matka ❋ Satta Matka 143❋ Kalyan Night Matka..
Dive into this presentation and learn about the ways in which you can buy an engagement ring. This guide will help you choose the perfect engagement rings for women.
IMPACT Silver is a pure silver zinc producer with over $260 million in revenue since 2008 and a large 100% owned 210km Mexico land package - 2024 catalysts includes new 14% grade zinc Plomosas mine and 20,000m of fully funded exploration drilling.
Best Competitive Marble Pricing in Dubai - ☎ 9928909666Stone Art Hub
Stone Art Hub offers the best competitive Marble Pricing in Dubai, ensuring affordability without compromising quality. With a wide range of exquisite marble options to choose from, you can enhance your spaces with elegance and sophistication. For inquiries or orders, contact us at ☎ 9928909666. Experience luxury at unbeatable prices.
HR search is critical to a company's success because it ensures the correct people are in place. HR search integrates workforce capabilities with company goals by painstakingly identifying, screening, and employing qualified candidates, supporting innovation, productivity, and growth. Efficient talent acquisition improves teamwork while encouraging collaboration. Also, it reduces turnover, saves money, and ensures consistency. Furthermore, HR search discovers and develops leadership potential, resulting in a strong pipeline of future leaders. Finally, this strategic approach to recruitment enables businesses to respond to market changes, beat competitors, and achieve long-term success.
NIMA2024 | De toegevoegde waarde van DEI en ESG in campagnes | Nathalie Lam |...BBPMedia1
Nathalie zal delen hoe DEI en ESG een fundamentele rol kunnen spelen in je merkstrategie en je de juiste aansluiting kan creëren met je doelgroep. Door middel van voorbeelden en simpele handvatten toont ze hoe dit in jouw organisatie toegepast kan worden.
Ellen Burstyn: From Detroit Dreamer to Hollywood Legend | CIO Women MagazineCIOWomenMagazine
In this article, we will dive into the extraordinary life of Ellen Burstyn, where the curtains rise on a story that's far more attractive than any script.
Profiles of Iconic Fashion Personalities.pdfTTop Threads
The fashion industry is dynamic and ever-changing, continuously sculpted by trailblazing visionaries who challenge norms and redefine beauty. This document delves into the profiles of some of the most iconic fashion personalities whose impact has left a lasting impression on the industry. From timeless designers to modern-day influencers, each individual has uniquely woven their thread into the rich fabric of fashion history, contributing to its ongoing evolution.
2. OUR FIELDS:
PHARMACEUTICALS. CHEMICALS. LIFE SCIENCE.
At Merck, around 39,000 people in 66 countries develop pharmaceutical, chemical and life science innovations. We operate our businesses in four divisions:
Merck Serono, Consumer Health, Performance Materials and Merck Millipore.
PHARMACEUTICALS: We discover, develop, manufacture and commercialize
innovative prescription drugs and therapies for high unmet medical needs.
Through their targeted effect, these help patients to live a longer and better
life (Merck Serono).
In addition, for the consumer health care market, we offer a wide range
of over-the-counter products that help prevent illness and relieve minor
complaints (Consumer Health).
3_013_FACTS+FIGURES_EN.indd 2
13.03.13 15:0
3. CE.
CHEMICALS: Our broad range of specialty chemicals are used in
t
echnologically sophisticated applications ranging from liquid crystal
mixtures for flat-panel displays, to effect pigments and cosmetic
ingredients (Performance Materials).
LIFE SCIENCE: As a leading global partner to this future-oriented industry,
we offer products, applications and solutions for protein research and
cell biology as well as for the manufacture of chemical and biopharmaceutical drugs. Our products and services range from laboratory chemir
cals, eagents and consumables to analytical methods and laboratory
p
water urification systems (Merck Millipore).
3_013_FACTS+FIGURES_EN.indd 3
13.03.13 15:0
5. We are convinced that in our core pharmaceutical, chemical and life science
businesses, the market will reward successful research and technological
a
dvances with attractive margins. Our focus is on innovative specialty products. Competing on price alone and operating in commodity markets is not
what we do.
We have a clear objective: profitable growth. This is based on a distinct,
fundamental strategy that can be summed up in three words: Sustain.
Change. Grow. It’s a strategy based on the right balance between the old
and the new, between tradition and innovation. It gives us the best possible
preconditions for future growth and makes it possible to fully unleash our
entrepreneurial potential.
Our strategy and our ethical company values give our employees clear
o
rientation for their daily work. We enable them to share in the company’s
success and, thus, also in the execution risk. This way, we will remain
c
urious and courageous – and continue to seize many new opportunities
in the future.
3_013_FACTS+FIGURES_EN.indd 5
13.03.13 15:0
7. MERCK SERONO:
EFFECTIVE MEDICINES TO FIGHT
DAUNTING OPPONENTS.
Merck Serono is the largest division of Merck and focuses on specialist
t
herapeutic areas such as oncology, multiple sclerosis, growth disorders,
and infertility. The division offers innovative prescription drugs of chemical
and biological origin.
We are proud of our innovative products – and we invest around € 1 billion
in R&D every year in our core therapeutic areas Oncology, Multiple Sclerosis
and Immunology.
Endocrinology:
General Medicine:
3_013_FACTS+FIGURES_EN.indd 7
Saizen® (growth hormone disorders),
Serostim® (HIV-associated wasting),
Kuvan® (metabolic disorder hyperphenylalaninemia),
Egrifta™ (HIV-associated lipodystrophy)
Glucophage® franchise (type 2 diabetes),
Concor® franchise (cardiovascular diseases),
Euthyrox® (thyroid disorders)
13.03.13 15:0
8. KEY ProDUCTS:
Mobility:
Products to strengthen the joints and relieve pain, including the brands
Seven Seas® and Kytta®
Cough and cold:
Cold treatment Nasivin® (Iliadin®); Sedalmerck® for pain relief
3_013_FACTS+FIGURES_EN.indd 8
13.03.13 15:0
9. CONSUMER HEALTH:
PREVENTING MINOR AILMENTS
AND PROTECTING HEALTH.
Many consumers around the world trust a wide range of well-known brands
with scientifically based mechanisms of action that Merck develops, manufactures and markets for the OTC (over-the-counter) pharmaceutical sector. Our focus in the Consumer Health division is on eight strategic brands,
specializing in key aspects of health care, such as mobility, everyday health
protection, women’s health, cough and cold, and allergies. Our scientifically
based product portfolio is aligned to the needs of consumers worldwide.The
main distribution channels are pharmacies, as well as retail chains, drugstores
and mail order in some countries.
Everyday health protection:
Probiotic multivitamin products from the Bion® and Multibionta® ranges
Vitamins and minerals sold under brand names such as Cebion® and Diabion®
Women’s and children’s health:
Femibion®, products with folic acid and Metafolin® for pregnant and
nursing women; Kidabion® (Haliborange®), a vitamin product range for
c
hildren; Sangobion® for iron deficiency
3_013_FACTS+FIGURES_EN.indd 9
13.03.13 15:0
10. KEY ProDUCTS:
licristal® Liquid crystal mixtures for displays
Isiphor® Lighting materials for energy-efficient, high-quality LED lighting
livilux®
Materials for OLEDs (organic light-emitting diodes)
isishape®
Efficient, eco-friendly materials for structuring solar cells and
touchscreens
3_013_FACTS+FIGURES_EN.indd 10
13.03.13 15:0
11. PERFORMANCE MATERIALS:
LCDs, EFFECT PIGMENTS AND MORE.
Merck is the global leader in the liquid crystals market. Liquid crystals are
used throughout the world, in LCD TVs, monitors, tablet computers, notebooks,
and mobile phones. In addition, the Performance Materials division focuses
on materials for energy-saving lighting using LEDs (light-emitting diodes) and
OLEDs (organic LEDs) as well as for OLED smartphone displays.
Pigments for the coatings, plastics and printing industries as well as for
c
osmetic applications are an important part of the Performance Materials
portfolio. Moreover, the division is the market leader for pearl luster effect
p
igments – a highly specialized niche within the pigment market.
Iriodin®, Xirallic ®, Colorstream ®
Effect pigments for use in coatings, packaging and product design
Timiron®, Colorona®, Ronaflair ®, Xirona®
Effect and functional pigments for cosmetic formulations
Ronacare®
Cosmetic active ingredients for skin care
3_013_FACTS+FIGURES_EN.indd 11
13.03.13 15:0
12. KEY ProDUCTS:
Products for life science research in the pharmaceutical and biotechnology
industries
Products for protein research and cell biology including consumables,
reagents and services to help customers better understand diseases and
biological functions
3_013_FACTS+FIGURES_EN.indd 12
13.03.13 15:0
13. MERCK MILLIPORE:
PRODUCTS AND SERVICES FOR PHARMACEUTICAL RESEARCH AND BIOTECHNOLOGY.
With the Merck Millipore division, Merck is a leading life science tools
c
ompany. The portfolio comprises products and services for the life science
industry such as assays, biomarkers and target solutions, as well as bioprocessing, lab water purification and filtration. These are used by customers
working in research and analytical laboratories as well as in pharmaceutical
manufacturing. Additionally, the division supplies specialty chemicals mainly
to regulated markets, for example the pharmaceutical, cosmetics and food
industries. Analytical and scientific laboratories use the reagents and test kits
supplied by the division. The Merck Millipore portfolio comprises more than
60,000 products and processes.
Laboratory chemicals and materials for research, science and industry
Products and services for sampling and assay platforms for the pharmaceutical,
food and diagnostics industries
Products, consumables and services for ultrapure laboratory water in science
and industry
Products that help to develop and manufacture pharmaceutical and biopharmaceutical drugs safely and efficiently
3_013_FACTS+FIGURES_EN.indd 13
13.03.13 15:0
15. • Extended indication of the multiple sclerosis drug Rebif® was approved
in Europe in 2012 for use in patients who have experienced a single
demyelinating event, an early sign of the disease.
• The targeted oncology drug Erbitux® is currently approved for use in colorectal cancer in 92 countries and in head and neck cancer in 90 countries.
• Merck Serono researchers are currently working on 16 projects in
drug development.
• With innovative liquid crystal mixtures for polymer-stabilized vertical
alignment (PS-VA) applications, we further expanded our technology leadership. PS-VA technology opens up new possibilities for LCD producers to
achieve previously unattained screen properties.
• Organic light-emitting diodes (OLEDs) convert electricity most efficiently
into light and can be produced as thin, flexible films. Application possibilities
include displays, for example in mobile phones or small televisions.
• With Scepter™, the Merck Millipore division launched the world’s first automated handheld cell counter.
• For photovoltaics, Merck supplies materials for the cost-efficient production
of solar cells and develops new materials, e.g. for flexible, organic solar cells.
• Merck is working on innovative lighting materials, such as those for
p
ower-saving white LEDs, which may represent an alternative to conventional
incandescent light bulbs and energy-saving lamps.
3_013_FACTS+FIGURES_EN.indd 15
13.03.13 15:0
16. MERCK MANAGEMENT:
THE MEMBERS OF THE EXECUTIVE BOARD.
3_013_FACTS+FIGURES_EN.indd 16
Karl-Ludwig Kley, Chairman
Born in 1951, lawyer
Member of the Merck Supervisory Board and Board of Partners
from March 2004 to June 2006; on the Merck Executive Board
since September 2006.
Responsible for Group functions:
Group Strategy, Group Communications, Group Legal
and Compliance, Group Internal Auditing
Kai Beckmann, Head of Human Resources /
Chief Administration Officer
Born in 1965, university degree in computer science
Joined Merck in 1989; on the Merck Executive Board
since April 2011.
Responsible for Group functions:
Group Human Resources, Group Information Services,
Site Operations, Inhouse Consulting
Stefan Oschmann,
responsible for the Merck Serono
and Consumer Health divisions
Born in 1957, veterinarian
On the Merck Executive Board since January 2011.
Responsible for Group functions:
Patents Scientific Services
13.03.13 15:0
17. 3_013_FACTS+FIGURES_EN.indd 17
Bernd Reckmann,
responsible for the Performance Materials
and Merck Millipore divisions
Born in 1955, biochemist
Joined Merck in 1986; on the Merck Executive Board
since January 2007.
Responsible for Group functions:
Environment, Health, Safety, Security, Quality
Matthias Zachert, Chief Financial Officer
Born in 1967, university degree in business
On the Merck Executive Board since June 2011.
Responsible for Group functions:
Group Accounting Subsidiaries, Group Controlling Risk
Management, Corporate Finance, Group Tax, Group Insurance,
Group Procurement, Investor Relations
13.03.13 15:0
18. MERCK AT A GLANCE:
KEY FIGURES FOR 2012.
In 2012, the Merck Group generated total revenues of € 11.2 billion.
The Merck Serono division accounted for € 6.4 billion, the Consumer Health
division for € 475 million, the Performance Materials division for € 1.7 billion
and the Merck Millipore division for € 2.6 billion of that total. EBITDA pre,
with which the earning power of operating activities is measured, climbed to
€ 3 billion.
Research and development spending amounted to € 1.5 billion. The operating
result totaled € 964 million and free cash flow was € 2 billion.
MERCK ONLINE:
SERVICE LINKS.
Important and current information on the company can be found on the Web at
www.merckgroup.com
The following websites offer information on special topics:
www.merckgroup.com/darmstadt, www.merckgroup.com/investors,
www.merckgroup.com/history, www.merckgroup.com/responsibility,
www.merckgroup.com/innovations
Up-to-date articles and reports on Merck, its fields of activity and products can be found at:
www.merckgroup.com/explorermagazine
Brochures and audiovisual media on Merck’s activities can be ordered from
Group Communications or downloaded from www.merckgroup.com/publications
3_013_FACTS+FIGURES_EN.indd 18
13.03.13 15:0
19. m
m
Se
r
ch
pm
Total revenues by division (in € million)
Merck Serono
6,405
M
erck Millipore
2,617
Performance Materials
1,676
Consumer Health
475
Operating result by division* (in € million)
Merck Serono
mm
508
M
erck Millipore
233
pm
ch
Ser
Performance Materials
599
Consumer Health
4
*excluding Corporate and Other
Sales by region (in € million)
N
orth America
2,128
Emerging Markets
3,712
EU
NA
Emerg Ma
3_013_FACTS+FIGURES_EN.indd 19
Rest
Europe
3,943
Rest of World
958
13.03.13 15:0
20. The Merck Group. An overview.
Published in March 2013
by Merck KGaA, Group Communications,
Frankfurter Strasse 250, 64293 Darmstadt, Germany
Phone: +49 (0) 6151-72 0
Fax: +49 (0) 6151-72 5577
E-mail: comms@merckgroup.com
Website: www.merckgroup.com
Photos: Robert Wilson, Torben Conrad
Concept and design: Nissen Carstensen GmbH
Lithography: data-graphis GmbH
Printing: Frotscher Druck GmbH, Darmstadt
W 840 103
3_013_FACTS+FIGURES_EN.indd 20
13.03.13 15:0